BPA Biosante Pharmaceuticals

BioSante Pharmaceuticals (AMEX:BPA) today announced that Stephen M. Simes, president and chief executive officer, will present a corporate overview at two upcoming conferences. The conferences are: The Bio International Convention on May 8, 2007 at 3:45 p.m. EDT at the Boston Convention and Exhibition Center. The Rodman & Renshaw Global Healthcare Conference on May 14, 2007 at 12:15 p.m. local time at the Le Meridien Hotel in Monte Carlo. A live audio webcast of BioSante�s presentation at these conferences can be accessed on the internet by visiting www.biosantepharma.com. An archive of these presentations will be available at the same address. The Bio International Convention is expected to attract more than 20,000 biotech leaders, investors and analysts from around the world and features over 1,000 speakers. The Rodman & Renshaw Global Healthcare Conference has over 200 companies presenting to investors, stock analysts and industry representatives from around the world. About BioSante Pharmaceuticals, Inc. BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bio-identical estradiol and testosterone. BioSante's lead products include Elestrin� (estradiol gel), developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and LibiGel� (transdermal testosterone gel) in Phase III clinical development for the treatment of female sexual dysfunction (FSD). The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion. The transdermal gel formulations used in the women's gel products are licensed by BioSante from Antares Pharma. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including hepatitis B, avian flu and biodefense vaccines for toxins such as anthrax, as well as a system for delivering drugs via alternative routes of administration. Additional information is available online at: www.biosantepharma.com.